Blog Archive
-
▼
2007
(90)
-
▼
November
(14)
- Vectura and Sosei, Phase II Studies of QVA149 for ...
- Aeolus Pharmaceuticals, Pipeline, COPD
- Amira Pharmaceuticals, Initiates Clinical Studies ...
- NicOx, TOPIGEN initiates phase 2 proof of concept ...
- SPO Medical, New Oximetry Devices for European Mar...
- Advanced Life Sciences, Cethromycin, Second Pivota...
- Pharmion's Amrubicin, Results Compared to Standard...
- MAP Pharmaceuticals, Phase 2a Clinical Trial of Co...
- Gilead and LG Life Sciences, Global License Agreem...
- Æterna Zentaris, Multi-Center Phase 2 Trial with P...
- Alfacell's ONCONASE, Radiation Sensitizer for Lung...
- Nabi Biopharmaceuticals, NicVAX(R) , Significant R...
- Forbes Medi-Tech, Final Steps in Compound Selecti...
- Theravance, Initiation of Phase 2 Clinical Program...
-
▼
November
(14)
Nov 19, 2007
SPO Medical, New Oximetry Devices for European Markets
November 14, 2007 - ...The PulseOx 6000™ (finger device) and PulseOx 6100™ (hand-held device) are both designed for medical professionals, hospitals and managed care facilities. Based on SPO Medical’s proprietary patented algorithms, both the PulseOx 6000™ and PulseOx 6100™ use Reflective Pulse Oximetry (RPO) technology for accurate and reliable measurements of blood oxygen saturation and heart rate, utilizing new AutoSpot™ technology to read in low profusion measurements. The products have been granted CE Mark of approval by the European Union and will be commercially available early in the first quarter of 2008... [PDF] SPO Medical's Press Release -